دورية أكاديمية
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
| العنوان: | The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer |
|---|---|
| المؤلفون: | Albert Grinshpun, Sara M. Tolaney, Harold J. Burstein, Rinath Jeselsohn, Erica L. Mayer |
| المصدر: | npj Breast Cancer, Vol 9, Iss 1, Pp 1-4 (2023) |
| بيانات النشر: | Nature Portfolio, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the first-line setting for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Randomized trials have demonstrated similar and significant improvements in progression-free survival using the three available CDK4/6 inhibitors and led to regulatory approval. However, mature overall survival data now suggest potential differences among the various agents, suggesting an evolution in selection preferences. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2374-4677 50643924 |
| العلاقة: | https://doaj.org/toc/2374-4677Test |
| DOI: | 10.1038/s41523-023-00520-7 |
| الوصول الحر: | https://doaj.org/article/0064d50643924f538eaaf8da5ed4adbeTest |
| رقم الانضمام: | edsdoj.0064d50643924f538eaaf8da5ed4adbe |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 23744677 50643924 |
|---|---|
| DOI: | 10.1038/s41523-023-00520-7 |